0.80
-1.25%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pliant Therapeutics
From its filings with the US Securities and Exchange Commission
Pliant Therapeutics is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PLRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $149.3m. At that date it held total assets of $225.2m and shareholders' equity of $181.2m.
We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is focused on the development of treatments for solid tumors by inhibiting integrin-mediated activation of transforming growth factor-β (TGF-β). We have applied our deep understanding of integrin biology, along with our medicinal chemistry and translational medicine expertise to develop a proprietary drug discovery platform that we believe has broad applicability across multiple areas of disease.
Our wholly owned lead product candidate, PLN-101095, is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins in development for the treatment of solid tumors. In 2025, we announced positive data from a Phase 1 open-label dose-escalation trial of PLN-101095 as monotherapy and in combination with the immunotherapy pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. We also continue to explore the full potential of our drug discovery platform consisting of a proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery.
Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Jun 2020
- Employees
- 49
- Website
- pliantrx.com ↗
- Head office
- 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Hoyoung HuhNon-Executive Chairman of the Board, Lead Independent Director$304,650
- Dr. Bernard CouliePresident, Chief Executive Officer, Director, since 2016$6.6m
- Dr. Keith CummingsChief Financial Officer$3.1m
- Ms. Minnie KuoChief Operating Officer
- Ms. Lily CheungChief Human Resources Officer
- Dr. Delphine ImbertChief Technical Officer
- Dr. Suzanne BruhnIndependent Director$282,800
- Mr. Darren ClineIndependent Director$279,525
- Ms. Gayle CrowellIndependent Director$287,600
- Dr. John CurnutteIndependent Director$276,800
- Dr. Katharine KnobilIndependent Director$284,100
- Mr. Steven KrognesIndependent Director$501,138
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 35
- Environment
- 4
- Social
- 33
- Governance
- 67
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pliant Therapeutics Inc is a leading biopharmaceutical company dedicated to the discovery and development of novel therapies for fibrotic diseases. Their strong research and development capabilities enable the company to identify promising drug candidates.
- The company has a talented team of scientists and researchers who bring extensive expertise in the field of fibrosis, allowing them to understand the disease mechanisms and develop targeted treatments.
Weaknesses
- One of the potential weaknesses of Pliant Therapeutics Inc is their heavy dependence on the success of their drug candidates in clinical trials. If any of their major trials fail or experience significant delays, it could have a negative impact on the company's reputation and financial stability.
- Another weakness is the competitive nature of the biopharmaceutical industry, with many rival companies also focused on developing therapies for fibrotic diseases. Pliant Therapeutics Inc needs to continuously innovate and stay ahead of their competitors to maintain their market position.
Opportunities
- The growing prevalence of fibrotic diseases presents a significant market opportunity for Pliant Therapeutics Inc. As the population ages, the incidence of fibrosis-related conditions is expected to increase, creating a larger patient pool for potential treatments.
- Additionally, partnerships and collaborations with academia, research institutions, and other biopharmaceutical companies can provide Pliant Therapeutics Inc with access to new technologies, resources, and expertise that can accelerate their drug development efforts.
Threats
- One of the major threats to Pliant Therapeutics Inc is the stringent regulatory environment governing drug development and commercialization. The company needs to ensure strict compliance with regulatory requirements to gain approval for their therapies, which can be a time-consuming and expensive process.
- Another threat is the possibility of unforeseen side effects or adverse events associated with their drug candidates. Safety concerns can lead to setbacks, regulatory scrutiny, and potential lawsuits, which could negatively impact the company's reputation and financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.